EUCTR2010-021069-63-SK进行中（未招募）1 期
A randomized, placebo, controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide Once Weekly in patients with type 2 diabetes mellitus - EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL)
Amylin Pharmaceuticals, LLC0 个研究点目标入组 14,000 人开始时间: 2011年2月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient has type 2 diabetes mellitus
- •- Patient will able to see a usual care provider at least twice a year
- •- Patient has an HbA1c of = 6.5% and = 10.0% and is currently using one of the following treatment regimens:
- •Treatment with up to three (i.e., 0-3) oral AHAs (concomitant use of DPP-4 inhibitors is permitted).
- •Insulin therapy, either alone or in combination with up to two (ie., 0-2) oral AHAs (use of basal and prandial insulins is permitted in any combination of individual or premixed insulins)
- •All patients should be on a stable diabetes management regimen, as assessed by the investigator, at the time of enrollment.
- •- Patients with any level of CV risk.
- •- Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.
- •- Patient agrees to provide permission to obtain all medical records necessary for complete data ascertainment during the follow-up period, and agrees to communication between the trial site and the usual care provider in order to facilitate routine care.
- •- Patient is 18 years or older at enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3500
排除标准
- •- Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.
- •- Patient has a history (= 2 episodes) of severe hypoglycemia within 12 months of enrollment.
- •- Patient has ever been treated with an approved or investigational GLP-1 receptor agonist e.g. exenatide BID, exenatide once weekly, liraglutide, lixisenatide, albiglutide, taspoglutide, or dulaglutide.
- •- Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.
- •- Patient has a planned or anticipated revascularization procedure.
- •- Pregnancy or planned pregnancy during the trial period.
- •- Patient has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance which, in the opinion of the investigator or coordinator, might pose an unacceptable risk to the patient, confound the results of the trial e.g. if patient cannot comply with requirements of the trial, or likely to interfere with the patient’s participation for the full duration of the trial.
- •- Patient has end-stage renal disease or an estimated glomerular filtration rate of <30 mL/min/1.73 m2.
- •- Patient has a history of gastroparesis.
- •- Personal or family history of medullary thyroid cancer or MEN2 (Multiple Endocrine Neoplasia Type 2) or calcitonin level > 40ng/L at baseline.
- •- Patient has previously been enrolled in EXSCEL.
- •- Patient has a history of pancreatitis.
- •- Is an employee of Amylin Pharmaceuticals LLC, Bristol-Myers Squibb Company or AstraZeneca.
研究者
相似试验
已完成
3 期
A randomized, placebo, controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide Once Weekly in patients with type 2 diabetes mellitusnon-insulin dependent diabetesType 2 diabetes mellitus10018424NL-OMON41366Amylin Pharmaceuticals, LLC204
进行中（未招募）
1 期
A Study to Test the Effects of Exenatide Once Weekly on Cardiovascular Outcomes in Patients with Type 2 DiabetesType 2 diabetes mellitusMedDRA version: 17.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021069-63-BEAmylin Pharmaceuticals, LLC14,000
进行中（未招募）
1 期
A Study to Test the Effects of Exenatide Once Weekly on Cardiovascular Outcomes in Patients with Type 2 DiabetesEUCTR2010-021069-63-LTAmylin Pharmaceuticals, LLC14,000
进行中（未招募）
1 期
A Study to Test the Effects of Exenatide Once Weekly on Cardiovascular Outcomes in Patients with Type 2 DiabetesType 2 diabetes mellitusMedDRA version: 19.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021069-63-HUAmylin Pharmaceuticals, LLC14,000
进行中（未招募）
1 期
A Study to Test the Effects of Exenatide Once Weekly on Cardiovascular Outcomes in Patients with Type 2 Diabetes.Type 2 diabetes mellitusMedDRA version: 17.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021069-63-GBAmylin Pharmaceuticals, LCC14,752